Underlying conditions and trigger diseases for the development of aHLH: comparison of (A) the global perspective, summarized by Ramos-Casals et al,⁶  and (B) the highly selected refractory aHLH cohort studied by Wang et al.¹  Of note, given the restricted composition of trigger diseases, the prospectively designed salvage trial for aHLH with DEP regimen achieved meaningful results, whereas a one-size-fits-all treatment algorithm is not appropriate for all potential aHLH patients, as causes and trigger diseases are highly heterogeneous, requiring individualized, risk-adapted treatment.⁵  Hem NPL, hematologic neoplasia; HSCT, hematopoietic stem cell transplantation; NPL, neoplasia; Organ-sp AID, organ-specific autoimmune disease; SLE, systemic lupus erythematosus.